دورية أكاديمية
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
| العنوان: | Maintenance therapy for multiple myeloma with particular emphasis on thalidomide. |
|---|---|
| المؤلفون: | Dürk HA; Klinik für Hämatologie/Onkologie, St. Marien-Hospital Hamm, Germany. heinz.duerk@marienhospital-hamm.de |
| المصدر: | Onkologie [Onkologie] 2006 Dec; Vol. 29 (12), pp. 582-90. Date of Electronic Publication: 2006 Dec 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Karger Country of Publication: Switzerland NLM ID: 7808556 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0378-584X (Print) Linking ISSN: 0378584X NLM ISO Abbreviation: Onkologie Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, New York, Karger. |
| مواضيع طبية MeSH: | Dexamethasone/*therapeutic use , Interferon-alpha/*therapeutic use , Multiple Myeloma/*drug therapy , Multiple Myeloma/*prevention & control , Prednisone/*therapeutic use , Thalidomide/*therapeutic use, Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Humans ; Practice Guidelines as Topic ; Practice Patterns, Physicians'/trends ; Thalidomide/adverse effects ; Treatment Outcome |
| مستخلص: | Treatment standards are changing as a result of new findings in the therapy of multiple myeloma. So far, prednisone, dexamethasone and interferon-a have mainly been used as maintenance therapy after achieving remission or stable disease. At present, thalidomide is being considered as a new therapeutic option in several studies investigating maintenance therapy. As a result of the dose dependence of adverse effects such as neuropathy, constipation, sedation/vertigo and bradycardia, individual adjustment of the thalidomide dose is recommended. Only isolated cases of thrombosis occurred in the maintenance phase of therapy, and discontinuation of therapy is generally not necessary. While important study results on the efficacy of thalidomide following conventional chemotherapy are still awaited, it is the best documented drug so far for maintenance therapy following autologous stem cell transplantation. An upgrade of the response was seen in 22-73% of patients, as well as a significant prolongation of progression-free survival. For the first time, maintenance therapy with thalidomide showed a significant improvement in overall survival in a phase III study published recently. The tolerability of thalidomide could be further improved by including the option of intermittent administration of the drug. |
| Number of References: | 64 |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Antineoplastic Agents) 0 (Interferon-alpha) 4Z8R6ORS6L (Thalidomide) 7S5I7G3JQL (Dexamethasone) VB0R961HZT (Prednisone) |
| تواريخ الأحداث: | Date Created: 20070105 Date Completed: 20070130 Latest Revision: 20151119 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1159/000096262 |
| PMID: | 17202830 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0378-584X |
|---|---|
| DOI: | 10.1159/000096262 |